LT2970303T - Pakeistieji ksantinai ir jų panaudojimo metodai - Google Patents

Pakeistieji ksantinai ir jų panaudojimo metodai

Info

Publication number
LT2970303T
LT2970303T LTEP14722452.1T LT14722452T LT2970303T LT 2970303 T LT2970303 T LT 2970303T LT 14722452 T LT14722452 T LT 14722452T LT 2970303 T LT2970303 T LT 2970303T
Authority
LT
Lithuania
Prior art keywords
canties
changed
use methods
methods
changed canties
Prior art date
Application number
LTEP14722452.1T
Other languages
English (en)
Lithuanian (lt)
Inventor
Bertrand Chenard
Randall Gallaschun
Original Assignee
Hydra Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2970303(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hydra Biosciences, Inc. filed Critical Hydra Biosciences, Inc.
Publication of LT2970303T publication Critical patent/LT2970303T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP14722452.1T 2013-03-15 2014-03-14 Pakeistieji ksantinai ir jų panaudojimo metodai LT2970303T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789724P 2013-03-15 2013-03-15
PCT/US2014/027920 WO2014143799A2 (en) 2013-03-15 2014-03-14 Substituted xanthines and methods of use thereof

Publications (1)

Publication Number Publication Date
LT2970303T true LT2970303T (lt) 2017-07-25

Family

ID=50680155

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14722452.1T LT2970303T (lt) 2013-03-15 2014-03-14 Pakeistieji ksantinai ir jų panaudojimo metodai

Country Status (31)

Country Link
US (7) US9359359B2 (enExample)
EP (1) EP2970303B3 (enExample)
JP (1) JP6360149B2 (enExample)
KR (1) KR102227629B1 (enExample)
CN (2) CN107082782B (enExample)
AU (1) AU2014228206C1 (enExample)
CA (1) CA2899646C (enExample)
CL (1) CL2015002738A1 (enExample)
CY (1) CY1119042T1 (enExample)
DK (1) DK2970303T6 (enExample)
EA (1) EA028815B1 (enExample)
ES (1) ES2636835T7 (enExample)
HR (1) HRP20170840T4 (enExample)
HU (1) HUE033528T4 (enExample)
IL (1) IL240216B (enExample)
LT (1) LT2970303T (enExample)
MX (1) MX370372B (enExample)
MY (1) MY189912A (enExample)
NZ (1) NZ711718A (enExample)
PE (1) PE20151779A1 (enExample)
PH (1) PH12015502141B1 (enExample)
PL (1) PL2970303T6 (enExample)
PT (1) PT2970303T (enExample)
RS (1) RS56066B2 (enExample)
SG (1) SG11201506479TA (enExample)
SI (1) SI2970303T1 (enExample)
TW (1) TWI609867B (enExample)
UA (1) UA117470C2 (enExample)
UY (1) UY35488A (enExample)
WO (1) WO2014143799A2 (enExample)
ZA (1) ZA201505414B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
DK2970303T6 (en) 2013-03-15 2018-10-08 Hydra Biosciences Inc SUBSTITUTED XANTHINES AND PROCEDURES FOR USING IT
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン誘導体
WO2016159746A1 (en) 2015-03-27 2016-10-06 Latvian Institute Of Organic Synthesis Novel ethynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis
WO2016159747A1 (en) 2015-03-27 2016-10-06 Latvian Institute Of Organic Synthesis Ethynylxanthines, preparation and use as calcium ion channel modulators
WO2016159745A1 (en) 2015-03-27 2016-10-06 Latvian Institute Of Organic Synthesis Ethynylxanthines, preparation and use for cancer treatment
DK3280417T3 (da) * 2015-04-08 2020-11-02 Lewis And Clark Pharmaceuticals Inc Xanthin-substitueret alkynyl karbamater/omvendte karbamater som a2b antagonister
CN107118586A (zh) * 2016-02-24 2017-09-01 中国科学技术大学 含氮杂环基取代的烯类化合物的用途
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
US11666577B2 (en) * 2017-02-28 2023-06-06 National Institute Of Biological Sciences, Beijing MLKL inhibitors
WO2018157800A1 (en) * 2017-02-28 2018-09-07 National Institute Of Biological Sciences, Beijing Mlkl inhibitors
PL3652176T3 (pl) * 2017-07-11 2022-04-04 Boehringer Ingelheim International Gmbh Podstawione pochodne ksantyny
EP3761989A4 (en) * 2018-03-05 2021-11-24 Goldfinch Bio, Inc. IMIDAZODIAZEPINEDIONE AND METHOD OF USE THEREOF
AU2019396499B2 (en) * 2018-12-12 2024-10-10 Boehringer Ingelheim International Gmbh Substituted xanthine derivatives
EP3894409B1 (en) 2018-12-12 2023-08-23 Boehringer Ingelheim International GmbH Substituted xanthine derivatives
CN112979651B (zh) * 2021-04-09 2022-02-01 南京纽邦生物科技有限公司 一种副黄嘌呤的制备方法
CN113354646B (zh) * 2021-07-06 2022-11-15 南开大学 8-芳氧基烷氧基取代黄嘌呤衍生物及其制备方法和应用
CN115636831B (zh) * 2022-10-27 2024-11-08 中国药科大学 稠合嘧啶二酮类化合物、其用途以及药物组合物
WO2024133476A1 (en) 2022-12-20 2024-06-27 Boehringer Ingelheim International Gmbh Process for the preparation of 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione
WO2024153028A1 (zh) * 2023-01-20 2024-07-25 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
WO2024165540A1 (en) 2023-02-06 2024-08-15 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione
CN118459461A (zh) 2023-02-08 2024-08-09 中国科学院上海药物研究所 黄嘌呤类化合物及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4304650A1 (de) * 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
JP4191269B2 (ja) 1996-05-17 2008-12-03 興和株式会社 新規なアニリド化合物及びこれを含有する医薬
JPH10318487A (ja) 1997-05-16 1998-12-04 Mitsubishi Gas Chem Co Inc 真空断熱材用ゲッタ
US6075029A (en) * 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
US6187780B1 (en) * 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
JP2002541258A (ja) * 1999-04-09 2002-12-03 セル セラピューティクス インコーポレーテッド インターリューキン−12シグナルを阻害するための治療用化合物及びその使用方法
ES2244634T3 (es) * 2000-07-04 2005-12-16 Novo Nordisk A/S Purina-2,6-dionas como inhibidoras de la enzima dipeptidil peptidasa iv (ddp-iv).
AU2002239508B9 (en) 2000-12-07 2005-09-08 Gilead Palo Alto, Inc. Substituted 1, 3, 5-triazines and pyrimidines as ABCA-1 elevating compounds against coronary artery disease or atherosclerosis
HU230384B1 (hu) * 2001-02-24 2016-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
NZ532816A (en) * 2001-11-09 2005-11-25 Cv Therapeutics Inc A2B adenosine receptor antagonists
MXPA05011860A (es) * 2003-05-06 2006-02-17 Cv Therapeutics Inc Derivados de xantina como antagonistas del receptor de adenosina a2b.
CA2545944A1 (en) 2003-11-13 2005-06-02 Board Of Regents, The University Of Texas System Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
US7393827B2 (en) 2004-12-30 2008-07-01 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring β-cell mass and function
US8143254B2 (en) 2005-02-18 2012-03-27 Cornell Research Foundation, Inc. Methods for modulating ion channels
EP1912992A1 (en) * 2005-08-10 2008-04-23 SmithKline Beecham Corporation Xanthine derivatives as selective hm74a agonists
ATE459620T1 (de) 2005-09-06 2010-03-15 Glaxosmithkline Llc Benzimidazolthiophenverbindungen als plk- modulatoren
CA2631885A1 (en) 2005-12-07 2007-06-14 Ucb Pharma, S.A. Xanthine derivatives, processes for preparing them and their uses
CN101384261B (zh) * 2005-12-22 2011-12-07 海德拉生物科学公司 治疗疼痛的组合物
US20070232673A1 (en) 2006-01-19 2007-10-04 Roth Gregory P 2-Imino-benzimidazoles
WO2007101213A2 (en) 2006-02-28 2007-09-07 Kalypsys, Inc. Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
WO2008011518A2 (en) * 2006-07-19 2008-01-24 Diakine Therapeutics, Inc. Encapsulation system
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
US20120148604A1 (en) 2009-08-20 2012-06-14 Transposagen Biopharmaceuticals, Inc. Trp inhibitors and uses thereof
WO2011114184A1 (en) * 2010-03-15 2011-09-22 Glenmark Pharmaceuticals S.A. Amides of heterocyclic compounds as trpa1 inhibitors
US9260430B2 (en) 2010-06-08 2016-02-16 Hydra Biosciences, Inc. Use of TRPA1 antagonists to prevent or treat infections caused by biological-warfare agents
JP2013023102A (ja) 2011-07-22 2013-02-04 Panasonic Corp 列車情報提供システム
BR112014002960A2 (pt) * 2011-08-09 2017-02-21 Cubist Pharm Inc inibição de canal de íons potencial receptor transiente trpa1
CN103121970B (zh) 2012-12-04 2015-04-29 中国科学院昆明植物研究所 苯并咪唑及其衍生物,其药物组合物及其在制备抗抑郁药物中的应用
DK2970303T6 (en) 2013-03-15 2018-10-08 Hydra Biosciences Inc SUBSTITUTED XANTHINES AND PROCEDURES FOR USING IT

Also Published As

Publication number Publication date
PL2970303T3 (pl) 2017-08-31
DK2970303T6 (en) 2018-10-08
CA2899646C (en) 2021-08-31
US20160237089A1 (en) 2016-08-18
US20190322667A1 (en) 2019-10-24
US9969736B2 (en) 2018-05-15
CL2015002738A1 (es) 2016-06-10
IL240216B (en) 2018-11-29
SI2970303T1 (sl) 2017-08-31
EP2970303B1 (en) 2017-05-10
IL240216A0 (en) 2015-09-24
US20170305910A1 (en) 2017-10-26
SG11201506479TA (en) 2015-09-29
RS56066B2 (sr) 2018-09-28
CA2899646A1 (en) 2014-09-18
US9359359B2 (en) 2016-06-07
AU2014228206A1 (en) 2015-09-24
EP2970303B3 (en) 2018-08-01
PT2970303T (pt) 2017-06-23
US20250034143A1 (en) 2025-01-30
CY1119042T1 (el) 2018-01-10
RS56066B1 (sr) 2017-10-31
US20140275071A1 (en) 2014-09-18
MX2015011617A (es) 2016-04-25
PH12015502141B1 (en) 2018-10-12
MX370372B (es) 2019-12-11
DK2970303T5 (en) 2018-01-02
PL2970303T6 (pl) 2018-12-31
BR112015021164A8 (pt) 2019-12-03
UY35488A (es) 2014-10-31
HUE033528T4 (en) 2018-05-02
PE20151779A1 (es) 2015-11-20
EP2970303B9 (en) 2017-09-20
KR20150133233A (ko) 2015-11-27
KR102227629B1 (ko) 2021-03-16
UA117470C2 (uk) 2018-08-10
AU2014228206C1 (en) 2018-10-25
WO2014143799A9 (en) 2014-12-24
DK2970303T3 (en) 2017-06-26
ES2636835T7 (es) 2018-11-20
US11958854B2 (en) 2024-04-16
ES2636835T3 (es) 2017-10-09
CN105143229B (zh) 2017-06-30
US20180244674A1 (en) 2018-08-30
EA028815B1 (ru) 2018-01-31
US11208409B2 (en) 2021-12-28
BR112015021164A2 (pt) 2017-07-18
EP2970303A2 (en) 2016-01-20
WO2014143799A2 (en) 2014-09-18
HK1217329A1 (zh) 2017-01-06
ZA201505414B (en) 2016-03-30
JP6360149B2 (ja) 2018-07-18
AU2014228206B2 (en) 2018-05-10
HUE033528T2 (hu) 2017-12-28
TW201533044A (zh) 2015-09-01
CN107082782B (zh) 2020-03-20
EA201591615A1 (ru) 2016-05-31
HRP20170840T4 (hr) 2018-11-16
PH12015502141A1 (en) 2016-01-25
CN107082782A (zh) 2017-08-22
US20230040259A1 (en) 2023-02-09
WO2014143799A4 (en) 2015-02-12
WO2014143799A3 (en) 2014-11-06
MY189912A (en) 2022-03-21
TWI609867B (zh) 2018-01-01
NZ711718A (en) 2020-05-29
JP2016513717A (ja) 2016-05-16
HRP20170840T1 (hr) 2017-09-08
CN105143229A (zh) 2015-12-09
US10399982B2 (en) 2019-09-03

Similar Documents

Publication Publication Date Title
LT2970303T (lt) Pakeistieji ksantinai ir jų panaudojimo metodai
DK3043784T3 (da) Arylethere og anvendelser deraf
IL245036B (en) Pesticidal compositions and related methods
LT3003039T (lt) Metil/fluor-piridinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai ir fluor-pirimidinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai
FR3014828B1 (fr) Trottinette motorisee
DK3381917T3 (da) Imidazopyridinforbindelser og anvendelser deraf
LT2968443T (lt) Hepcidino analogai ir jų naudojimas
LT3051939T (lt) Sėklų rūšies pasirinkimo būdai ir sistemos
LT3071597T (lt) Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
LT3363438T (lt) Pakeistieji 2-azabiciklai ir jų panaudojimas kaip oreksino receptorių moduliatorių
DK2986722T3 (da) Manipulerede phenylalaninammoniak-lyasepolypeptider
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
LT3030519T (lt) Tricikliniai benzoksaborolo junginiai ir jų naudojimas
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3029038T3 (da) Tetrazolinonforbindelse og anvendelse deraf
IL244214B (en) Thienopiperidine derivative and its use
PL3563837T3 (pl) Terapia bakteriofagami
LT3337506T (lt) Deriniai ir jų panaudojimas
LT3060660T (lt) Rekombinantiniai glikoproteinai ir jų naudojimas
EP3048883C0 (en) PESTICIDE COMPOSITION AND ASSOCIATED PROCESS
EP3047192A4 (en) LOCKABLE LOCATED CONNECTOR
HRP20180520T1 (hr) Suncobran